Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
Muhammad Saleem Iqbal Khan, Sumbal Arooj, Hua Wang
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

BTLA biology in cancer: from bench discoveries to clinical potentials
Anna Andrzejczak, Lidia Karabon
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 19
Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach
Subhamay Adhikary, Surajit Pathak, Vignesh Palani, et al.
Biomedicines (2024) Vol. 12, Iss. 1, pp. 217-217
Open Access | Times Cited: 10
Soluble B7 and TNF family in colorectal cancer: Serum level, prognostic and treatment value
Mina Monfared, Sina Nazmi, Forough Parhizkar, et al.
Human Immunology (2025) Vol. 86, Iss. 2, pp. 111232-111232
Closed Access | Times Cited: 1
Exploring a specialized programmed-cell death patterns to predict the prognosis and sensitivity of immunotherapy in cutaneous melanoma via machine learning
Leyang Xiao, Ruifeng He, Kaibo Hu, et al.
APOPTOSIS (2024) Vol. 29, Iss. 7-8, pp. 1070-1089
Closed Access | Times Cited: 8
Modern cancer therapy: cryoablation meets immune checkpoint blockade
Qi Liu, Chun‐yang Zhang, Xuxin Chen, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review
Fatemeh Eskandari-Malayeri, Marzieh Rezaei
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 25
Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer types
Lirui Dai, Xuyang Guo, Zhe Xing, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Trispecific antibodies for cancer immunotherapy
Yin Yao, Yiyin Hu, Fei Wang
Immunology (2023) Vol. 169, Iss. 4, pp. 389-399
Open Access | Times Cited: 13
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Michael Kuske, Maximilian Haist, T. Jung, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1710-1710
Open Access | Times Cited: 22
Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives
Mohammad Sadegh Soltani‐Zangbar, Forough Parhizkar, Mojtaba Abdollahi, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 21
B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma
Cristina Bottino, Chiara Vitale, Alessandra Dondero, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3279-3279
Open Access | Times Cited: 11
The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study
Takashi Kurosaki, Kenji Chamoto, Shinichiro Suzuki, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
Masaud Shah, Muhammad Hussain, Hyun Goo Woo
Genomics & Informatics (2025) Vol. 23, Iss. 1
Open Access
Immunological Network Signature of Naïve Non-Oncogene-Addicted Non-Small Cell Lung Cancer Patients Treated with Anti-PD1 Therapy: A Pilot Study
Pasquale Sibilio, Ilaria Grazia Zizzari, Alain Gelibter, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 922-922
Open Access
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao, et al.
BioDrugs (2025)
Closed Access
Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors
Piotr Wawrzyniak, Mariusz L. Hartman
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Epigenetic regulators combined with tumour immunotherapy: current status and perspectives
Huan Zhang, Yuepeng Pang, Ling Yi, et al.
Clinical Epigenetics (2025) Vol. 17, Iss. 1
Open Access
Innate immune checkpoint SIRPα/CD47 blockade ameliorates silica-induced pulmonary fibrosis by modulating macrophage immunity
Youliang Zhao, Meixiu Duan, Yuanmeng Qi, et al.
International Immunopharmacology (2025) Vol. 156, pp. 114723-114723
Closed Access
The Current and Future of Biomarkers of Immune Related Adverse Events
William Bracamonte‐Baran, Sang T. Kim
Immunology and Allergy Clinics of North America (2025) Vol. 45, Iss. 2, pp. 223-249
Closed Access
Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology
Elena Muraro, Rebecca Romanò, Giuseppe Fanetti, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 175, pp. 103707-103707
Closed Access | Times Cited: 18
Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future
Menglu Pan, Huanhuan Zhao, Ruimin Jin, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Implications of oral dysbiosis and HPV infection in head and neck cancer: from molecular and cellular mechanisms to early diagnosis and therapy
Marian Constantin, Mariana Carmen Chifiriuc, Grigore Mihăescu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 9
miRNAs Related to Immune Checkpoint Inhibitor Response: A Systematic Review
José Luis García‐Gimenez, Wiam Saadi, Ángel Ortega, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1737-1737
Open Access | Times Cited: 3
Shining a LIGHT on myeloid cell targeted immunotherapy
Casey W. Shuptrine, Vincent M. Perez, Sara R. Selitsky, et al.
European Journal of Cancer (2023) Vol. 187, pp. 147-160
Open Access | Times Cited: 9
Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1
Adam Mor, Marianne Strazza
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top